CytoDyn Inc. (CYDY)
CYDY is quoted over the counter, not listed on an exchange. CytoDyn Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-16.
Profile
| Field | Value |
|---|---|
| Ticker | CYDY, quoted over the counter |
| SEC CIK | 0001175680 |
| OTC Markets tier | OTCQB (price source, 2026-11-13) |
| SEC industry code | Pharmaceutical Preparations |
| Business address | Vancouver, WA |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors, among others, including the various matters discussed in Note 10, Commitments and Contingencies , raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-10-14 |
| Cash and burn | $16.4M cash; operating cash flow -$5.6M a quarter. | Report 2026-08-31 |
| Shares outstanding | 1,469,518,000 (2026-09-30); 1,259,753,000 a year earlier; 931,151,762 three years earlier. | Cover page 2026-09-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-09-25 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | CBIZ CPAs P.C., Hartford, Connecticut, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-05-16 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2027 2026-08-31 | Not filed | -$19.9M | -$7.7M | $16.4M | $35.8M | Needs four quarters | 10-Q 2026-10-14 |
| Q4 2026 2026-05-31 | Not filed | -$9.9M | -$4.9M | $11.9M | $38.3M | Needs four quarters | 10-K 2026-08-31 |
| Q3 2026 2026-02-28 | Not filed | -$4.7M | -$5.5M | $15.7M | $40.5M | Needs four quarters | 10-Q 2026-04-08 |
| Q2 2026 2025-11-30 | Not filed | -$22.6M | -$4.3M | $5.0M | $42.2M | Needs four quarters | 10-Q 2026-04-08 |
| Q1 2026 2025-08-31 | Not filed | -$5.5M | -$2.5M | $9.3M | $43.8M | Needs four quarters | 10-Q 2026-10-14 |
| Q4 2025 2025-05-31 | Not filed | -$6.0M | -$5.7M | $11.9M | $45.4M | Needs four quarters | 10-K 2026-08-31 |
| Q3 2025 2025-02-28 | Not filed | -$4.8M | -$5.0M | $16.4M | $45.8M | Needs four quarters | 10-Q 2026-04-08 |
| Q2 2025 2024-11-30 | Not filed | -$4.8M | -$3.6M | $21.3M | $46.1M | Needs four quarters | 10-Q 2026-04-08 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-10-07 |
| Latest annual report | 10-K | 2026-08-31 |
| Latest quarterly / interim | 10-Q | 2026-10-14 |
| Latest current report | 8-K | 2026-10-19 |
| Latest proxy | DEFA14A | 2026-10-19 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier